Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links

  • About Us
  • Mission & Values
  • Leadership
  • News
  • Careers
  • Partnerships
  • Support
  • Achievements

Latest News

June 27, 2014

Request for Proposals: Clinical Trials of Immune Tolerance in Transplantation Using Deceased-Donor Organs

The Immune Tolerance Network (ITN) is currently seeking proposals for clinical tolerance trials in transplantation using solid organs or islets from deceased donors.

Proposals should meet the following criteria:

> read more
June 25, 2014

"Mechanisms of Tolerance" Symposium at Annual FOCIS Meeting

The ITN is hosting a Member Society Symposium entitled “Mechanisms of Tolerance” on June 25th, 2014 (12:45-pm-4:45pm CT) during the annual Federation of Clinical Immunology Societies (FOCIS) meeting in Chicago,  IL. The symposium features talks on emerging hypotheses of immune tolerance mechanisms:

Engrafting Tolerance using Hematopoeitic Stem Cells

> read more
May 06, 2014

Restoring the Balance: Immunotherapeutic Combinations for Autoimmune Disease

An article published last week in Disease Models and Mechanisms by Dawn Smilek, MD, PhD, Mario Ehlers, MD, PhD, and Jerry Nepom, MD, PhD, provides a review of mechanisms involved in the disruption of tolerance to self-antigens in autoimmune disease, highlighting where those mechanisms can be targeted as a means of restoring tol

> read more
February 21, 2014

ITN Launches the PAUSE Study in Psoriasis

Today the ITN launched the PAUSE study (ITN059AI, “Efficacy of Ustekinumab followed by Abatacept for the Treatment of Psoriasis Vulgaris”), which will test the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients. This study is being led by James Krueger, MD, PhD (The Rockefeller University).

> read more
February 18, 2014

Specimens and Funding for Type 1 Diabetes Biomarker Research

Creating durable disease remission in type 1 diabetes has proved challenging: etiology remains uncertain and immune interventions have only been able to delay disease progression temporarily. To better understand underlying disease pathways, the ITN conducts sophisticated mechanistic assays on high-quality specimens collected from each of its clinical trials. After a study is complete, unused mechanistic specimens are available to the scientific community for further research through the ITN’s Clinical Trials Research Portal, TrialShare.

> read more
February 17, 2014

New Publication: T Cell Reconstitution Following Autologous Stem Cell Transplant in Patients with Multiple Sclerosis

The promise of autologous stem cell transplantation in patients with autoimmune disease is that the newly reconstituted immune system will be reset in a way that no longer favors autoimmunity. The ITN’s HALT-MS study (High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis) used high-dose immunosuppression followed by an autologous stem cell transplant in 24 relapsing, remitting multiple sclerosis (MS) patients in an attempt to reconstitute a healthy immune system.

> read more
January 15, 2014

ITN wins NIH award for Collaborative Network for Tolerance Research

The National Institute of Allergy and Infectious Disease (NIAID/NIH) announced that the Immune Tolerance Network (ITN) has been awarded a UM1 grant for a Collaborative Network for Clinical Research on Immune Tolerance (RFA-AI-12-043). This award represents the third NIH funding disbursement since the ITN’s inception in 2000. The current grant, covering the next seven years, will allow the ITN to continue to develop, fund and implement mechanistically-focused clinical trials for novel therapies in transplantation, allergy and autoimmune diseases.

> read more
January 06, 2014

ACCEPTOR Kidney Transplant Study Opens for Enrollment

The ITN’s ACCEPTOR study (Post-transplant Cyclophosphamide) in kidney transplant is now open for enrollment at Johns Hopkins University.  The ACCEPTOR study, led by Lode Swinnen, MD, Ephraim Fuchs, MD, and Robert Montgomery, MD (Johns Hopkins Hospital) will combine hematopoietic stem cell (HSC) and kidney transplants as a means to potentially promote tolerance to the donor kidney.  

> read more
December 13, 2013

The Immune Tolerance Network Opens ANCA-associated Vasculitis Biomarker Study in the UK

The ITN’s AVATARS study in ANCA-associated Vasculitis (AAV) opened for enrollment today at the University College London. The AVATARS study (Defining Immune Tolerance in ANCA-associated Vasculitis) led by Alan Salama, MD, PhD (University College London) and Peter Merkel, MD (University of Pennsylvania) is a non-interventional, prospective study that will collect blood specimens from patients with AAV with the goal of identifying biomarkers of tolerance.

> read more
December 02, 2013

ITN Type 1 Diabetes Roundup at the International Diabetes Federation (IDF) and Immunology of Diabetes Society (IDS) Meetings

The International Diabetes Federation (IDF) annual meeting (December 2-6, 2013) and Immunology of Diabetes Society (IDS) annual meeting (December 7-11, 2013) in Australia will feature multiple talks on recent findings from the Immune Tolerance Network's ( ITN’s) portfolio of type 1 diabetes studies. Type 1 diabetes is a challenging disease where so far no therapeutic has been able to reverse or permanently halt the autoimmune attack on pancreatic β-cells.

> read more

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Next page Next ›
  • Last page Last »

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility